List of Nexavar drug patents

Nexavar is owned by Bayer Hlthcare.

Nexavar contains Sorafenib Tosylate.

Nexavar has a total of 3 drug patents out of which 0 drug patents have expired.

Nexavar was authorised for market use on 20 December, 2005.

Nexavar is available in tablet;oral dosage forms.

Nexavar can be used as treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment; treatment of advanced renal cell carcinoma; treatment of unresectable hepatocellular carcinoma, treatment of advanced renal cell carcinoma, treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, or differentiated thyroid carcinoma..

The generics of Nexavar are possible to be released after 10 September, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8877933 BAYER HLTHCARE Thermodynamically stable form of a tosylate salt
Dec, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618141 BAYER HLTHCARE Aryl ureas with angiogenesis inhibiting activity
Feb, 2023

(10 days from now)

US9737488 BAYER HLTHCARE Pharmaceutical composition for the treatment of cancer
Sep, 2028

(5 years from now)

Drugs and Companies using SORAFENIB TOSYLATE ingredient

Market Authorisation Date: 20 December, 2005

Treatment: Treatment of advanced renal cell carcinoma; Treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment; Treatment of unresectable hepatocellular carcinoma; Treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, or differentiated thyroid carcinoma.

Dosage: TABLET;ORAL

How can I launch a generic of NEXAVAR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic